TGFB1 and glaucoma: The results obtained from the ELISA analyses of TGFβ1 clearly defined an enhancement of the TGFβ1 levels in the retinal samples of the DEX-induced glaucoma control group whereas consistent treatment with OMT led to a dose-dependent decline, which is known to inhibit TGFβ1 selectively, thus putting enough emphasis on the impact of TGFβ1 hyperactivation in glaucoma and its resultant reduction.